DrugId:  1
1. Name:  Inclacumab
2. Groups:  Investigational
3. Description:  Inclacumab has been used in trials studying the treatment and prevention of Myocardial Infarction, Peripheral Arterial Disease (PAD), and Coronary Heart Disease, Graft Occlusion, Vascular.
4. Indication:  Not Available
DrugId:  2
1. Name:  Anisindione
2. Groups:  Approved
3. Description:  Anisindione is a synthetic anticoagulant and an indanedione derivative. It prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin K-mediated gamma-carboxylation of precursor proteins.
4. Indication:  For the prophylaxis and treatment of venous thrombosis and its extension, the treatment of atrial fibrillation with embolization, the prophylaxis and treatment of pulmonary embolism, and as an adjunct in the treatment of coronary occlusion.
DrugId:  3
1. Name:  99mTc-glucarate
2. Groups:  Investigational
3. Description:  99mTc-glucarate(GLA) is an agent for non-invasive detection of breast tumours.
4. Indication:  Investigated for use/treatment in myocardial infarction.
DrugId:  4
1. Name:  Alfimeprase
2. Groups:  Investigational
3. Description:  Alfimeprase is a recombinant analog of fibrolase. Fibrolase is a zinc-containing metalloproteinase isolated from the venom of the southern copperhead snake (Agkistrodon contortrix contortrix). It is a small protein that contains 203 residues (Randolph et al. 1992). Alfimeprase is being developed by Nuvelo.
4. Indication:  Alfimeprase is being evaluated as a potential treatment for acute ischemic stroke, catheter occlusion (CO) and acute peripheral arterial occlusion (PAO).
DrugId:  5
1. Name:  Isopentyl 2-cyanoacrylate
2. Groups:  Investigational
3. Description:  Isoamyl 2 Cyanoacrylate is under investigation in clinical trial NCT02698644 (Hysteroscopic Tubal Occlusion With the Use of Iso Amyl-2-cyanoacrylate).
4. Indication:  Not Available
DrugId:  6
1. Name:  Alferminogene Tadenovec
2. Groups:  Investigational
3. Description:  Alferminogene Tadenovec is Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease. Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration from a standard cardiac infusion catheter.
4. Indication:  Investigated for use/treatment in angina, coronary artery disease, and heart disease.
DrugId:  7
1. Name:  Lemuteporfin
2. Groups:  Investigational
3. Description:  Lemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer. It is intended for the treatment of beign prostatic hyperplasia.
4. Indication:  Intended for the treatment of benign prostatic hyperplasia and prostrate disorders.
DrugId:  8
1. Name:  Egaptivon pegol
2. Groups:  Investigational
3. Description:  ARC1779 is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. ARC1779 is being developed as a novel antithrombotic agent for use in patients with acute coronary syndromes. ARC1779 is a therapeutic oligonucleotide ("aptamer") which blocks the binding of the A1 domain of vWF to the platelet GPIb receptor, and thereby modulates platelet adhesion, activation, and aggregation under the high shear conditions of coronary arterial stenosis and plaque rupture.
4. Indication:  Platelet aggregation, thrombosis and acute coronary syndromes
DrugId:  9
1. Name:  Diaminohydroxypropanetetraacetic acid
2. Groups:  Approved, Investigational
3. Description:  Diaminohydroxypropanetetraacetic acid has been investigated for the treatment of Vascular Disease, Coronary Disease, Myocardial Ischemia, Coronary Restenosis, and Coronary Artery Disease, among others.
4. Indication:  Not Available
DrugId:  10
1. Name:  Pegnivacogin
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in thrombosis, coronary artery disease, and vascular diseases.
DrugId:  11
1. Name:  Ranibizumab
2. Groups:  Approved
3. Description:  Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline (tetracycline is not detectable in the final product). Ranibizumab is marketed under the name Lucentis®. It is indicated for the treatment of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
4. Indication:  For the treatment of patients with macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
DrugId:  12
1. Name:  KAI-1455
2. Groups:  Investigational
3. Description:  KAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting (CABG), congenital cardiac defect repair, and hip replacement and may protect against renal injury associated with contrast media. Several studies have demonstrated that epsilon PKC plays a key role in cytoprotection during periods of ischemia. In preclinical studies, KAI-1455 showed a dramatic reduction in infarct size when delivered prior to the ischemic insult.
4. Indication:  Investigated for use/treatment in ischemic reperfusion injury.
DrugId:  13
1. Name:  Fibroblast growth factor-1
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in coronary artery disease and peripheral vascular disease.
DrugId:  14
1. Name:  Fenoxaprop-ethyl
2. Groups:  Investigational
3. Description:  Fenoxaprop-ethyl (organic nitrate combined with L-arginine), is an oral proprietary nitrate therapeutic shown to induce coronary vasodilation while overcoming the significant problem of drug tolerance. Fenoxaprop-ethyl has been investigated to treat chronic angina, the chest pain that occurs from inadequate blood flow to the coronary arteries around the heart.
4. Indication:  Chronic angina and Coronary Artery Disease 
DrugId:  15
1. Name:  Regrelor
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in cardiac surgery, coronary artery disease, thrombosis, and transfusion.
DrugId:  16
1. Name:  Trafermin
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in coronary artery disease, peripheral vascular disease, periodontal disease, bone fractures, entero-related fistulae, and diabetic foot ulcers.
DrugId:  17
1. Name:  Atopaxar
2. Groups:  Investigational
3. Description:  Atopaxar has been investigated for the treatment of Coronary Artery Disease and Acute Coronary Syndrome.
4. Indication:  Not Available
DrugId:  18
1. Name:  Porfimer sodium
2. Groups:  Approved, Investigational
3. Description:  The purified component of hematoporphyrin derivative, it consists of a mixture of oligomeric porphyrins. It is used in photodynamic therapy (hematoporphyrin photoradiation); to treat malignant lesions with visible light and experimentally as an antiviral agent. It is the first drug to be approved in the use of photodynamic therapy in the United States.
4. Indication:  Indicated in the treatment of esophageal cancer.
DrugId:  19
1. Name:  D-Treitol
2. Groups:  Experimental
3. Description:  A four-carbon sugar that is found in algae, fungi, and lichens. It is twice as sweet as sucrose and can be used as a coronary vasodilator. [PubChem]
4. Indication:  Not Available
DrugId:  20
1. Name:  Meso-Erythritol
2. Groups:  Experimental
3. Description:  A four-carbon sugar that is found in algae, fungi, and lichens. It is twice as sweet as sucrose and can be used as a coronary vasodilator. [PubChem]
4. Indication:  Not Available
DrugId:  21
1. Name:  TAFA-93
2. Groups:  Investigational
3. Description:  TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation, the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary artery disease.
4. Indication:  Investigated for use/treatment in transplant (rejection).
DrugId:  22
1. Name:  Gadolinium
2. Groups:  Approved, Investigational
3. Description:  Gadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease. Gadolinium has been investigated for the basic science of CAD, Multiple Sclerosis, and Coronary Artery Disease.
4. Indication:  Not Available
DrugId:  23
1. Name:  ARC183
2. Groups:  Investigational
3. Description:  ARC183 is a DNA aptamer, which is a single-stranded DNA molecule consisting of 15 deoxynucleotides that forms well-defined three-dimensional configuration, allowing it to bind to thrombin with high affinity and specificity. The keyadvantage of ARC183 compared to other thrombin inhibitors is its rapid onset of action and short half-life, giving it the potential to be an ideal agent for medical procedures that require rapid resolution of anticoagulation or that require reversal of anticoagulation shortly after the procedure is completed.
4. Indication:  Investigated for use/treatment in blood (blood forming organ disorders, unspecified), cardiac surgery, and coronary artery disease.
DrugId:  24
1. Name:  SR-123781A
2. Groups:  Investigational
3. Description:  SR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).
4. Indication:  Investigated for use/treatment in cardiovascular disorders, thrombosis, and venous thromboembolism.
DrugId:  25
1. Name:  MC-1
2. Groups:  Investigational
3. Description:  Medicure's MC-1 drug is a cardio-protectant, designed to reduce the damage to the heart when arteries are blocked and when they are subsequently reopened after bypass surgery.
4. Indication:  Investigated for use/treatment in coronary artery disease.
